Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06835179 |
TitleSBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. | Phase
Phase 2
|
Date Added 2025-02-19 |
Location |
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06841159 |
TitlePersonalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2025-03-25 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06850103 |
TitleSCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer with Oligometastases | Phase
Phase 2
|
Date Added 2025-03-25 |
Location |
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06856837 |
Title– IKF/AIO-QUINTIS – Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases | Phase
Phase 2
|
Date Added 2025-03-04 |
Location
Austria
Germany |
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06764680 |
TitleOral Chemotherapy, Targeted Therapy and Immunotherapy With/without Radiotherapy As 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer | Phase
Phase 2
|
Date Added 2025-01-08 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06412198 |
TitleA Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations | Phase
Phase 1, Phase 2
|
Date Added 2024-05-14 |
Location
Massachusetts, United States
Texas, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Adagrasib, cemiplimab, cetuximab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06415851 |
TitleChemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab | Phase
Phase 2
|
Date Added 2024-05-15 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06455254 |
TitleCadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM | Phase
Phase 2
|
Date Added 2024-06-12 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT05726864 |
TitleA Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2023-02-14 |
Location
Arizona, United States
California, United States Colorado, United States Florida, United States Georgia, United States Iowa, United States Louisiana, United States Massachusetts, United States Michigan, United States Minnesota, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Wisconsin, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
ELI-002 7P |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05768503 |
TitleComparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC | Phase
Phase 3
|
Date Added 2023-03-14 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Control Rx, Experimental drug |
Tags
MSS/ MMRp
|
